Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess theSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in HealthyParticipants

Trial Profile

A Randomized, Double-Blind, Multiple Ascending Dose Study to Assess theSafety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in HealthyParticipants

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ACH-0145228 (Primary) ; Ciprofloxacin
  • Indications Autoimmune disorders
  • Focus Adverse reactions; First in man
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 26 Jul 2019 Status changed from recruiting to completed.
    • 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, based on the results from this study the company plans to advance ACH-5228 into Phase 2 clinical trials in multiple diseases.
    • 22 Jul 2019 According to an Achillion Pharmaceuticals Media Release, the company expects to submit an IND application to the U.S. Food and Drug Administration supporting clinical development for ACH-5228 in the fourth quarter of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top